DACOTIN - OXALIPLATIN

Indications

Listed in Dosage.

Dosage

Adult: IV Advanced colorectal cancer W/ fluorouracil and folinic acid: 85 mg/m² 2 wkly. After recovery from toxicity, reduce to 65 mg/m². Administer before fluoropyrimidines. IV Adjuvant therapy in Stage III colon cancer 85 mg/m² 2 wkly, given for 12 cycles. After recovery from toxicity, reduce to 75 mg/m². Administer before fluoropyrimidines.
Click to view oxaliplatin Dosage by Indications

Overdosage

For action to be taken in the event of accidental overdose ... click to view oxaliplatin

Contraindications

Pregnancy. Peripheral neuropathy with functional impairment. Severe renal impairment.

Special Precautions

Should be administered under the supervision of an experienced cancer chemotherapy physician. Use appropriate precautions for handling and disposal. Monitor neurological status and dose should be reduced if symptoms are prolonged or severe. Monitor blood counts during treatment and courses should not be repeated until blood counts have recovered. Caution in elderly, moderate degrees of renal impairment. Avoid using aluminum-containing needles or IV admin sets that may come into contact with oxaliplatin as aluminum has been reported to cause degradation of platinum compounds. Lactation.

Adverse Drug Reactions

Fatigue, fever, pain, headache, insomnia, nausea, diarrheoa, vomiting, abdominal pain, constipation, anorexia, stomatitis, anemia, thrombocytopenia, leukopenia, aspartate and alanine transaminases increased, total bilirubin increased, peripheral neuropathy, back pain, dyspnoea, cough, oedema, chest pain, peripheral oedema, flushing , thromboembolism, dizziness, rash, alopecia , hand-foot syndrome dehydration, hypokalaemia, dyspepsia, taste perversion, flatulence, mucositis, gastroesophageal reflux, dysphagia, dysuria, neutropenia, inj site reaction, rigors, arthralgia, abnormal lacrimation, serum creatinine increased, rhinitis, epistaxis, pharyngitis, pharyngolaryngeal dysesthesia, allergic reactions, hiccup.
Potentially Fatal: Anaphylaxis, pulmonary fibrosis.

Drug Interactions

May decrease plasma levels of digoxin. May increase risk of toxicity with nephrotoxic drugs. When administered as sequential infusions, taxane derivatives (docetaxel, paclitaxel) should be administered before oxaliplatin to limit myelosuppression and enhance efficacy.

Pregnancy Category (US FDA)

Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).

Mechanism of Action

For details of the mechanism of action, pharmacology and pharmacokinetics and toxicology ... click to view oxaliplatin

CIMS Class

Cytotoxic Chemotherapy

ATC Classification

L01XA03 - oxaliplatin ; Belongs to the class of platinum-containing antineoplastic agents. Used in the treatment of cancer.